Cubist to buy Trius for $652mm, plus CVRs
Executive Summary
Cubist Pharmaceuticals Inc. (acute care) is acquiring public infectious disease-focused Trius Therapeutics Inc. for $13.50 per share in cash (a 17% premium), or $651.6mm. Trius stockholders will also receive contingent value rights (CVRs), entitling them to up to $2.00 for each share they own based on the achievement of certain sales goals.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice